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Background. Revascularization of infarcted myocardium results in release of inﬂammatory cytokines mediating myocardial
reperfusion injury and heart failure. Blockage of inﬂammatory pathways dampens myocardial injury and reduces infarct size. We
compared the impact of the interleukin-1 receptor antagonist Anakinra and erythropoietin on myocardial ischemia/reperfusion
injury. In contrast to others, we hypothesized that drug administration prior to reperfusion reduces myocardial damage. Methods
and Results. 12–15week-old Lewis rats were subjected to myocardial ischemia by a 1hr occlusion of the left anterior descending
coronary artery. After 15min of ischemia, a single shot of Anakinra (2mg/kg body weight (bw)) or erythropoietin (5000IE/kg
bw) was administered intravenously. In contrast to erythropoietin, Anakinra decreased infarct size (P<0.05, N = 4/group) and
troponin T levels (P<0.05, N = 4/group). Conclusion. One-time intravenous administration of Anakinra prior to myocardial
reperfusion reduces infarct size in experimental ischemia/reperfusion injury. Thus, Anakinra may represent a treatment option in
myocardial infarction prior to revascularization.
1.Introduction
Acute total occlusion of a coronary artery is regarded as the
underlying cause of acute myocardial infarction (AMI), one
of the most common causes of sudden cardiac death in the
western world [1, 2]. Several large-scale clinical trials have
demonstrated the importance of early reperfusion strategies
to improve the extent of myocardial damage as well as pa-
tient outcome [3]. So far, current guidelines recommend the
interventional treatment via percutaneous transluminal cor-
onary angioplasty (PTCA) of the culprit coronary lesion
followed by stent implantation in the setting of AMI, while
operative myocardial revascularization—if needed—should
generally be performed several days later [4, 5]. However,
randomized clinical trials concerning this topic are missing.
Arguments against coronary artery bypass surgery (CABG)
in AMI include the idea of an overwhelming reperfusion
injury caused by prolonged ischemia that may negatively in-
ﬂuence the beneﬁt of operative myocardial revascularization
[6]. In addition, CABG in AMI may include the enhanced
risk for perioperative complications and worsening of myo-
cardial inﬂammation by exposing the patient to extracorpo-
real circulation. Various studies have proven that myocardial
reperfusion itself results in an inﬂammatory response that
ultimately leads to cell death and possible loss of cardiac
function. The underlying mechanisms include the interplay
of a multitude of inﬂammatory mediators [7]. In this con-
text, Interleukin (IL)-1α and β via their receptor IL-1 type
I and activation of nuclear factor (NF)κB act as classical
inﬂammatory cytokines, mediating leukocyte chemotaxis,2 The Scientiﬁc World Journal
macrophage activation, reactive oxygen species formation,
endothelial dysfunction, and cardiomyocyte apoptosis [8, 9].
Thus, inhibition of IL-1 receptor activation has been recog-
nized as an interesting anti-inﬂammatory target. For exam-
ple, enhanced levels of intrinsic IL-1 receptor antagonist
(IL1-Ra) can be found during acute myocardial infarction,
which correlate with the extent of infarct size [10, 11]. Anak-
inra is a nonglycosylated, recombinant human, competitive
inhibitor of IL-1α and β signaling through binding to the
IL-1 receptor. Anakinra has already been demonstrated to
possess cardioprotective properties in diﬀerent experimental
and clinical settings [12, 13]. While experimental evidence
foraprotectiveroleoferythropoietininmyocardialischemia
hasbeenpromising, clinicaltrialssofarhavenotbeenableto
proof this hypothesis. In particular, erythropoietin dosage,
way of application and treatment duration, may critically
inﬂuence study outcome [14]. In contrast to other studies,
we here hypothesized, that application of anti-inﬂammatory
drugs like Anakinra and erythropoietin already prior to
myocardial reperfusion might positively inﬂuence reperfu-
sion damage and, thereby, may qualify these drugs for con-
sideration as preclinical treatment options in the setting of
AMI.
2.MaterialandMethods
2.1. Animals. 12–15-week old male Lewis rats (Charles
River, Sulzfeld, Germany) weighing 280–350g were used
for ischemia/reperfusion experiments. All animals were kept
according to the Institutional guide for the care and use
of laboratory animals. All procedures were approved by the
Institution’s facility for Laboratory Animal Science.
2.2. Myocardial Ischemia/Reperfusion Injury. Rats were ini-
tially narcotized by inhalation of ether followed by a sub-
cutaneous injection of 20% urethane (0.75mL/100g) and
tracheal intubation. Maintenance of anesthesia was achieved
by inhalation of isoﬂurane (0.5–1.5% isoﬂurane/100%
oxygen). The left femoral vein was cannulated for drug
administration. Afterlateralthoracotomyandopening ofthe
pericardial sack, the left anterior descending artery (LAD)
was exposed and occluded by ligation using 5–0 Prolene
suture (Johnson&Johnson, Ethicon Biosurgery, USA). Ani-
mals were randomly assigned to 4 experimental groups (N =
4 animals/group). Group 1 (control) received a bolus of
physiological saline solution 15 minutes (min) after onset of
myocardial ischemia. Ischemia was maintained for 1 hour
(hr) followed by 3hrs of reperfusion. Group 2 (Anakinra)
received 2mg/kg body weight (bw) Anakinra (Kineret,
Amgen GmbH, Germany) 15min after onset of ischemia.
Group 3 (erythropoietin) was treated with 5000IE/kg bw
erythropoietin (Neorecormon, Hoﬀmann-La Roche Ltd.,
Germany) 15min after onset of ischemia. Both, group 2 and
3 underwent 1hr of myocardial ischemia followed by 3hrs
of reperfusion after which rats were sacriﬁced for further
analyses.
2.3. Assessment of Infarct Size and Area at Risk. After 3hrs
of reperfusion, the LAD was reoccluded, and stainings were
performed. In short, Evans blue dye (1%, 3–5mL, Sigma-
Aldrich, Germany) was injected into the beating right ven-
tricular cavity to distinguish between ischemic (area at risk)
and nonischemic myocardium. To determine the infarct size,
the heart was sliced into ﬁve 2mm thick sections, each was
weighed and incubated with a 1.5% (W/V) triphenyltetra-
zolium chloride (TTC) solution for 30min at 37◦C followed
by immersion in liquid-nitrogen frozen 2-methylbutane
solution for 10min. Sections were cryo-sliced into 60μm
slides. Photographs were taken, and the ischemic area at risk
(unstained by Evans blue dye) and the infarcted area (un-
stained by TTC) were measured in a blinded fashion using
the axio vision 3.1 software (Zeiss, Oberkochem, Germany).
In addition, infarct size and area at risk were weighed.
2.4. Systemic Inﬂammatory Cytokine Levels. To investigate
the possible impact of the diﬀerent treatment regimens on
circulating cytokine levels, sera of 2 animals per group were
pooled.Overall,4samplespergroupweresubjectedtoELISA
(RayBioRatCytokineAntibodyArray,RayBiotech,Norcross,
USA) following the manufacturer’s protocol.
2.5. Troponin T Levels. Troponin T (TnT) levels were
determinedasindicatorsofmyocardialinjury.Bloodsamples
were collected before the sacriﬁce of animals, centrifuged,
and the serum was frozen at −20◦C. Serum TnT was
measured using commercial kits (Roche Diagnostics, Basel,
Switzerland) following the manufacturer’s instructions.
2.6. Statistical Analysis. All results are expressed as mean ±
SEM.Groupswerecomparedusing1-wayANOVA.Variables
within a group were compared using a paired t-test. P values
≤ 0.05 were considered signiﬁcant.
3. Results
3.1.AnakinraApplied PriortoMyocardial Reperfusionbut Not
Erythropoietin Reduces Infarct Size. One-time intravenous
administration of 2mg/kg bw Anakinra prior to myocardial
reperfusion signiﬁcantly reduced infarct size (expressed as
infarct mass in relation to area at risk mass) compared
to animals that received erythropoietin or saline solution
(47.6 ± 6.0% versus 76.2 ± 12.9% and 77.1 ± 7.8%, N = 4
animals/group, P<0.05, Figure 1(a)). Area at risk did not
diﬀer between the groups (Figure 1(b)).
3.2.AnakinraApplied PriortoMyocardial Reperfusionbut Not
Erythropoietin Reduces Troponin T Levels. Troponin T (TnT)
levels, which have been demonstrated to correlate with in-
farct size in rats, were signiﬁcantly lower in Anakinra-treated
animals compared to rats receiving erythropoietin (40.4ng/
mL versus 57.8ng/mL, N = 4/group, P<0.05, Figure 2).
However, no signiﬁcant diﬀerence between Anakinra-treated
animals and untreated animals was observed. Levels of creat-
inkinase (CK) or CK-MB did not diﬀer between the groups
(data not shown) [15].
3.3. Anakinra and Erythropoietin Applied Prior to Myocardial
Reperfusion Do Not Inﬂuence Systemic Inﬂammatory CytokineThe Scientiﬁc World Journal 3
120
100
80
60
40
20
0
I
n
f
a
r
c
t
 
s
i
z
e
 
(
%
 
a
r
e
a
 
a
t
 
r
i
s
k
)
Anakinra Erythropoietin
n.s.
∗ ∗
Control
(a)
n.s.
n.s.
80
70
60
50
40
30
20
10
A
r
e
a
 
a
t
 
r
i
s
k
 
(
%
)
Anakinra Erythropoietin Control
(b)
Figure 1: (a) Impact of Anakinra and erythropoietin on infarct size. One-time intravenous administration of Anakinra prior to reperfusion
resultedinasigniﬁcantreductionofinfarctsizeexpressedasinfarctmassinrelationtoareaatriskmass(%)comparedtocontrolsoranimals
receiving erythropoietin (∗P<0.05, N = 4/group). (b) Impact of Anakinra and erythropoietin on area at risk. One-time intravenous
administration of Anakinra or erythropoietin prior to reperfusion did not signiﬁcantly inﬂuence area at risk (n.s. = non signiﬁcant, N =
4/group).
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Figure 2: Impact of Anakinra and erythropoietin on troponin
T levels. One-time intravenous administration of Anakinra prior
to reperfusion resulted in a signiﬁcant reduction of troponin T
levels compared to animals receiving erythropoietin (P<0.05,
N = 4/group), whereas no signiﬁcant diﬀerence compared to rats
receiving saline solution (control) was found.
Levels. To investigate whether modulation of inﬂammatory
signalingpathwaysbyapplicationofAnakinraorerythropoi-
etin may inﬂuence systemic cytokine levels, sera of animals
were subjected to ELISA (N = 4s a m p l e s / g r o u p ) .H o w e v e r ,
we did not ﬁnd any diﬀerences in cytokine levels between the
groups (Figure 3).
4. Discussion
In contrast to previous studies, we here hypothesized that
a one-time intravenous administration of the IL-1 receptor
antagonist Anakinra or erythropoietin already prior to
reperfusion may limit myocardial I/R injury. We report that
Anakinra, but not erythropoietin, reduces infarct size in
this experimental setting. Myocardial reperfusion has been
demonstrated to cause cardiomyocyte death, microvascular
dysfunction, ventricular arrhythmias, and, ultimately, loss
of cardiac function resulting in heart failure [7]. During
coronary artery occlusion, ischemia in the dependent tissue
results in change of cellular metabolism from aerobic to
anaerobic energy utilization. Rapid reperfusion, however,
may induce an uncontrolled formation of reactive oxygen
species that not only serve as chemoattractant for inﬂam-
matory cells, but may directly damage cell compartments,
such as mitochondria and the sarcoplasmic reticulum [16].
The ischemia-triggered rise in intracellular calcium load is
further worsened by reperfusion and may drive cell hyper-
contraction. The inﬂux of inﬂammatory cells into the area
of former ischemia contributes to all of these mechanisms.
Therefore, modulating the inﬂammatory reaction during
myocardial reperfusion has been an attractive target for
experimental as well as clinical trials. IL-1α and β via
activation of the IL-1 type I receptor have been indicated
to promote a multitude of inﬂammatory processes. In
addition, both cytokines have been implicated in cardiac4 The Scientiﬁc World Journal
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Figure 3: Impact of Anakinra and erythropoietin on circulating inﬂammatory cytokines. Representative pictures demonstrating no
diﬀerences in the relative expression levels of inﬂammatory cytokines depicted as black spots (N = 4 samples/group, + indicating positive
control spots, − indicating negative control spots). Cytokine panel (top) published with kind permission of RayBiotech, Inc.
remodeling and heart failure. Thus, blocking the IL-1 type I
receptor by Anakinra seems a promising therapeutic target.
A cardioprotective eﬀect of Anakinra has already been
proposed by the results of diﬀerent experimental studies. For
example, cardiac overexpression of IL-1 receptor antagonist
reduced infarct size in a rat model of myocardial infarc-
tion. The underlying mechanisms may involve a decrease
in cardiomyocyte apoptosis, as indicated by a study of
Abbate and colleagues [17]. In addition, Anakinra posi-
tively inﬂuences endothelial dysfunction, reduced oxidative
stress, and improved ventricular function in patients with
rheumatoid arthritis, a known risk factor for cardiovascular
events [18]. As indicated by the ﬁndings of many other
groups in experimental and clinical trials, time, dosage,
duration, and way of drug application may lead to essentially
diﬀerent results regarding myocardial reperfusion injury.
Based on these facts and in contrast to other groups, we
hypothesized that the extent of reperfusion injury may be
most eﬃciently inﬂuenced by administration of the anti-
inﬂammatorydrugalreadypriortoreperfusion.Thereby,the
experimental design ofthis study aimed at imitating not only
the possibility of a more speciﬁc prehospital treatment of
acute myocardial ischemia. Instead, we also speculated that
an anti-inﬂammatory drug administration prior to reperfu-
sion may improve the management of patients undergoing
coronary artery bypass surgery, as myocardial ischemia and
reperfusionplayanimportant roleinthissetting [19].Inthis
context, we also decided to apply Anakinra and erythropoi-
etinviaacentralvenousaccesssiteinordertoquicklyachieve
systemic drug circulation despite circulatory depression
during cardiac ischemia. To our knowledge, this approach
hasnotbeenreportedbyothergroupssofar.Asstatedabove,
we did not ﬁnd any eﬀect of erythropoietin on myocardial
infarct size in the study presented. Erythropoietin is a hema-
topoietic hormone primarily produced in the kidney in re-
sponsetohypoxia.However,besideitsimpactonhematopoi-
esis, erythropoietin also modulates cardiovascular cell func-
tion.Incontextwithmyocardialischemia,erythropoietinhas
been shown to decrease cardiomyocyte apoptosis in diﬀerent
experimental settings [20, 21]. In addition, erythropoietinThe Scientiﬁc World Journal 5
seemingly decreases the inﬂammatory response during myo-
cardial reperfusion by modulating nitric oxide release [22,
23]. However, onset and duration of treatment as well as
dosage may again be crucial for the extent and the kind of
biological impact achieved by erythropoietin. So far, clinical
trials involving erythropoietin treatment in acute myocardial
infarction in patients have failed to prove any beneﬁt [24].
Thus,furtherstudiesareneededtoclarifytheroleofthishor-
mone in myocardial ischemia and reperfusion. Neither ery-
thropoietin nor Anakinra modulated the levels of circulating
inﬂammatory cytokines in the study presented. We speculate
that this observation may either be due to the circumstance
that systemic cytokine levels may not reﬂect local processes.
Inaddition,thetimepointofsampleextractionmaynothave
been accurate in order to detect a modulation of the systemic
inﬂammatory state. To summarize, one-time application of
Anakinra prior to myo-cardial reperfusion—in contrast to
erythropoietin—leads to a decreased extent of experimental
myocardial I/R injury and, therefore, may not only be
considered as a treatment option after revascularization but
instead may also be beneﬁcial in the very early phase of acute
myocardial infarction.
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